Does the reflexive measurement of free PSA have a role in a tertiary cancer centre?

Journal of the Canadian Urological Association

Volumn 4, Issue 5, 2010, Pages 317-320

  Allard, Christopher ^a   Yip, Paul ^a   Blasutig, Ivan ^a   Hersey, Karen ^a   Fleshner, Neil ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957729819     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.09165     Document Type: Article

References (12)

1. Barry MJ. Prostate-specific antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344:1373-1377.
2. Gann PH, Jing MA, Catalona WJ, et al. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002;167:2427-2434.
3. Tornblom M, Norming U, Adolfsson J, et al. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. Urology 1999;53:945-950.
4. Vashi AR, Wojno KJ, Henricks W, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostatespecific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19-27.
5. Luderer AA, Chen Y-T, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves the diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-194.
6. Chen YT, Luderer AA, Thiel RP, et al. Using proportions of free to total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518-524.
7. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-1547.
8. McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-186.
9. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
10. Barry MJ. Screening for prostate cancer - the controversy that refuses to die. N Engl J Med 2009;360:1351-1354.
11. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
12. Uzzo RG, Pinover WH, Horwitz EM, et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 2003;61:754-759.